CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
View all episodes
By BiotechTV
4.3
77 ratings
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
4,417 Listeners
1,111 Listeners
950 Listeners
113,520 Listeners
336 Listeners
2,571 Listeners
5,659 Listeners
10,241 Listeners
87 Listeners
35 Listeners
21 Listeners
467 Listeners
1,478 Listeners
12 Listeners
0 Listeners
4 Listeners
3 Listeners
6 Listeners